コンテンツへスキップ
Merck

Percutaneous bone lesion ablation.

La Radiologia medica (2014-06-05)
Dimitrios K Filippiadis, Sean Tutton, Alexis Kelekis
要旨

Benign tumors and metastatic bone lesions can be treated by ablation techniques performed either alone or in combination with other percutaneous techniques. Ablation techniques include ethanol or acetic acid injection and thermal ablation by means of energy deposition [including laser, radiofrequency, microwave, cryoablation, radiofrequency ionization and magnetic resonance (MR)-guided high-intensity focused ultrasound (HIFU)]. Goal definition of the therapy is crucial: ablation techniques can be proposed as curative treatments in benign bone tumors or oligometastatic disease (<3 lesions). Alternatively, these techniques can be proposed as palliative treatments aiming at reduction of pain, local control of the disease and tumor decompression. Depending on the lesion's location ablation can be combined with cementation with or without further metallic augmentation; local tumor control can be enhanced by combining ablation with transarterial bland embolization or chemoembolization. Thermal ablation of bone and soft tissues is characterized by high success and relatively low rates of potential complications, mainly iatrogenic thermal damage of surrounding sensitive structures. Successful thermal ablation requires a sufficient ablation volume and thermal protection of the surrounding vulnerable structures. This article will describe the general principles governing ablation and the mechanism of action for each technique and in addition will review the literature about safety and effectiveness of percutaneous imaging-guided ablation for benign and malignant (primary and metastatic) lesions.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
エチルアルコール(純粋), 190 proof, for molecular biology
Sigma-Aldrich
酢酸, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
酢酸, glacial, ReagentPlus®, ≥99%
Sigma-Aldrich
酢酸, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
酢酸, glacial, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, 99.8-100.5%
Sigma-Aldrich
酢酸 溶液, suitable for HPLC
Sigma-Aldrich
エタノール, JIS special grade, ≥99.5%
Sigma-Aldrich
Reagent Alcohol, reagent grade
Sigma-Aldrich
エタノール, SAJ first grade, ≥99.5%
Sigma-Aldrich
酢酸, for luminescence, BioUltra, ≥99.5% (GC)
USP
氷酢酸, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
酢酸, ≥99.5%, FCC, FG
Sigma-Aldrich
酢酸, natural, ≥99.5%, FG
Sigma-Aldrich
エチルアルコール(純粋), 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
エタノール, purum, fine spirit, denaturated with 4.8% methanol, F25 METHYL1, ~96% (based on denaturant-free substance)
Supelco
エタノール-50, 50 mg/dL in H2O, ampule of 10 × 1.2 mL, certified reference material, Cerilliant®
Sigma-Aldrich
酢酸, ≥99.7%
Sigma-Aldrich
酢酸, JIS special grade, ≥99.7%
Supelco
エタノール-10, 10 mg/dL in H2O, pack of 10 × 1.2 mL ampules, certified reference material, Cerilliant®
Supelco
エタノール 溶液, certified reference material, 2000 μg/mL in methanol